Infacort: modified hydrocortisone for CAH in neonates & infants

Home / Infacort: modified hydrocortisone for CAH in neonates & infants
Infacort: modified hydrocortisone for CAH in neonates & infants
  • Company: Diurnal Limited
    • Product Overview: First-in-class hydrocortisone product for the lifelong treatment of adrenal disorders
    • Primary Indication: Congenital Adrenal Hyperplasia, (CAH), (Orphan)
    • Secondary Indication: Adrenal Insufficiency
    • Core Differentiator: Modified release hydrocortisone that mimics the physiological rhythm of cortisol
    • Development Stage: Phase 3
    • Opportunity: Available for License